wide
rang
respiratori
virus
identifi
caus
signific
morbid
mortal
among
transplant
recipi
includ
influenza
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
rhinoviru
human
metapneumoviru
hmpv
coronaviru
tabl
sever
featur
common
among
virus
transplant
popul
season
respiratori
viral
infect
among
transplant
recipi
usual
follow
gener
popul
virus
caus
rang
diseas
mild
congest
rhinorrhea
sever
tracheobronch
bronchiol
pneumonia
one
viru
exclus
associ
one
clinic
syndrom
ie
influenzalik
ill
croup
etc
diagnost
strategi
initi
broad
attempt
screen
recogn
virus
particular
emphasi
one
might
amen
therapi
transplant
recipi
often
present
mild
atyp
symptom
fever
may
absent
lung
transplant
recipi
exampl
may
initi
subject
symptom
short
breath
subtl
chang
pulmonari
function
test
without
typic
symptom
viral
shed
usual
prolong
among
transplant
recipi
prolong
shed
seen
even
use
antivir
therefor
may
contribut
increas
risk
resist
variant
emerg
transplant
recipi
higher
risk
infecti
complic
compar
immunocompet
host
respiratori
viral
infect
signific
risk
factor
subsequ
develop
fungal
bacteri
pneumonia
respiratori
viral
infect
appear
risk
factor
acut
chronic
reject
greatest
risk
lung
transplant
recipi
although
data
topic
literatur
conflict
pathogenesi
link
respiratori
viral
infect
reject
clearli
understood
pediatr
solid
organ
lung
transplant
recipi
appear
greatest
risk
respiratori
viral
infect
sever
cours
complic
potenti
nosocomi
pathogen
potenti
spread
staff
visitor
mild
upper
respiratori
ill
sinc
one
clinic
distinguish
diseas
caus
respiratori
virus
diagnosi
use
broad
rang
techniqu
consid
particularli
earli
period
transplant
augment
immunosuppress
respiratori
viral
season
serolog
use
diagnosi
acut
infect
use
epidemiolog
studi
case
influenza
although
sot
recipi
might
respond
antibodi
wane
quickli
even
infect
rapid
antigen
detect
avail
influenza
rsv
advantag
rapid
result
test
within
influenza
rapid
antigen
detect
test
high
specif
variabl
sensit
compar
assay
make
less
use
sot
recipi
oral
iv
ribavirin
use
well
although
patient
monitor
hemolyt
anemia
less
data
avail
efficaci
formul
treat
rsv
aerosol
ribavirin
igiv
palivizumab
rsvig
longer
produc
may
still
avail
locat
commerci
assay
distinguish
influenza
b
other
case
rsv
one
studi
document
sensit
one
rapid
test
method
nasal
wash
specimen
among
immunocompromis
patient
sensit
improv
bal
use
sever
studi
direct
fluoresc
antibodi
dfa
test
primari
patient
specimen
document
sensit
approach
pcr
certain
virus
dfa
test
limit
lack
reagent
virus
hmpv
rhinoviru
coronaviru
although
viral
cultur
previous
consid
prefer
diagnost
test
molecular
test
tend
provid
higher
yield
detect
wider
rang
virus
time
fashion
influenza
viral
cultur
advantag
allow
identif
influenza
strain
test
antivir
suscept
wide
rang
pcrbase
assay
detect
respiratori
virus
commerci
avail
mani
center
local
develop
assay
detect
select
virus
nucleic
acid
amplif
assay
appear
sensit
diagnost
tool
avail
allow
simultan
detect
broad
rang
respiratori
pathogen
singl
sampl
therefor
prefer
test
method
immunocompromis
patient
multiplex
pcr
assay
provid
advantag
identif
virus
routin
found
convent
method
includ
rhinoviru
hmpv
commerci
avail
multiplex
assay
differ
sensit
specif
differ
virus
notabl
adenoviru
new
assay
develop
address
limit
clinician
awar
perform
characterist
assay
use
influenza
pcr
distinguish
among
viral
subtyp
quantifi
viral
load
make
use
monitor
viral
shed
recent
rapid
pcrbase
assay
allow
rapid
result
within
hour
although
sensit
may
vari
among
viru
type
influenza
viru
orthomyxoviru
associ
signific
morbid
mortal
winter
season
three
main
viral
strain
associ
human
infect
name
influenza
influenza
influenza
b
new
strain
influenza
come
reassort
anim
human
virus
caus
global
pandem
last
influenza
season
pandem
influenza
viru
replac
prior
season
influenza
viru
recent
studi
perform
pandem
greatli
increas
knowledg
epidemiolog
influenza
infect
transplant
popul
risk
complic
appear
higher
sot
recipi
compar
gener
popul
particularli
incid
pneumonia
transplant
recipi
allograft
dysfunct
acut
reject
observ
sever
case
influenza
studi
observ
excess
influenzaassoci
morbid
mortal
sot
recipi
compar
gener
popul
rate
report
sever
influenza
vari
attribut
mortal
estim
ascertain
bias
toward
inclus
patient
sever
diseas
may
overestim
sever
influenza
sot
recipi
risk
factor
sever
influenza
sot
recipi
includ
use
antilymphocyt
globulin
diabet
mellitu
pneumonia
bacteri
fungal
coinfect
earli
infect
month
transplant
use
earli
antivir
therapi
consist
associ
reduc
rate
influenzaassoci
complic
admiss
icu
use
invas
ventil
death
patient
known
suspect
influenza
infect
isol
patient
standard
droplet
precaut
influenza
vaccin
import
measur
prevent
influenza
infect
two
type
influenza
vaccin
exist
inactiv
influenza
vaccin
intranas
liveattenu
influenza
vaccin
laiv
laiv
contraind
sot
recipi
close
contact
due
potenti
risk
dissemin
vaccin
strain
one
dose
season
intramuscular
trival
influenza
vaccin
standard
care
adult
two
dose
week
apart
recommend
children
year
age
immunogen
influenza
vaccin
variabl
sot
recipi
depend
type
organ
immunosuppress
regimen
use
composit
vaccin
howev
increas
data
report
benefici
effect
influenza
vaccin
sot
recipi
lung
transplant
recipi
vaccin
adjuv
influenza
vaccin
associ
reduc
incid
subsequ
influenza
infect
vs
unvaccin
patient
influenza
vaccin
also
associ
lower
risk
graft
loss
death
kidney
transplant
recipi
even
vaccin
patient
develop
influenza
reduct
sever
diseas
compar
unvaccin
patient
observ
influenza
vaccin
therefor
recommend
sot
recipi
household
member
tabl
influenza
vaccin
well
toler
sot
recipi
advers
event
vaccin
usual
mild
short
live
recent
studi
describ
develop
lowlevel
antihla
antibodi
kidney
transplant
recipi
receiv
multipl
dose
adjuv
influenza
vaccin
one
season
proven
associ
vaccin
develop
de
novo
antibodi
graft
reject
studi
requir
clarifi
potenti
associ
optim
time
vaccin
transplant
establish
gener
recommend
vaccin
least
month
post
transplant
although
earli
period
post
transplant
risk
influenzaassoci
complic
higher
antivir
prophylaxi
oseltamivir
may
altern
influenza
vaccin
case
contraind
expect
nonrespons
vaccin
random
control
trial
transplant
recipi
found
efficaci
prophylaxi
two
famili
drug
approv
treatment
influenza
name
inhibitor
neuraminidas
inhibitor
inhibitor
amantadin
rimantadin
activ
influenza
b
high
incid
antivir
resist
influenza
these
drug
longer
recommend
treatment
influenza
neuraminidas
inhibitor
includ
oral
oseltamivir
inhal
zanamivir
tabl
recommend
grade
transplant
recipi
receiv
antivir
therapi
neuraminidas
inhibitor
either
oseltamivir
zanamivir
influenza
suspect
although
earli
administr
antivir
associ
better
outcom
symptomat
patient
receiv
antivir
therapi
irrespect
symptom
onset
durat
antivir
therapi
least
day
antivir
therapi
may
prolong
case
persist
viral
shed
doubl
dose
oseltamivir
may
consid
sever
case
case
insuffici
respons
therapi
iv
drug
peramivir
zanamivir
also
use
select
case
intub
patient
concern
oral
absorpt
patient
influenza
infect
need
isol
standard
droplet
measur
trival
inactiv
influenza
vaccin
administ
sot
recipi
household
member
patient
influenza
vaccin
contraind
may
insuffici
respons
eg
therapi
acut
reject
earli
transplant
antivir
prophylaxi
oseltamivir
mg
od
durat
week
start
begin
influenza
season
may
propos
intraven
form
oseltamivir
zanamivir
also
avail
investig
drug
current
approv
intraven
peramivir
anoth
neuraminidas
inhibitor
approv
use
south
korea
japan
none
drug
specif
test
prospect
trial
sot
recipi
therapi
influenza
studi
perform
influenza
pandem
show
earli
treatment
oseltamivir
associ
decreas
mortal
admiss
icu
complic
outcom
sot
recipi
less
data
avail
zanamivir
appear
equal
effect
therapi
neuraminidas
inhibitor
may
associ
reduc
incid
allograft
dysfunct
lung
transplant
recipi
given
benefici
effect
earli
administr
antivir
drug
oseltamivir
zanamivir
therapi
start
empir
patient
symptom
compat
influenza
microbiolog
confirm
transplant
recipi
known
prolong
viral
replic
gener
recommend
extend
durat
therapi
beyond
approv
day
period
monitor
viral
replic
nasopharyng
swab
pcr
may
use
guid
durat
antivir
therapi
although
earli
administr
antivir
associ
better
outcom
patient
may
still
benefit
therapi
irrespect
durat
symptom
sever
case
doubl
dose
ie
mg
oseltamivir
twice
day
normal
kidney
function
recommend
expert
anecdot
case
posit
outcom
sot
recipi
report
literatur
importantli
pharmacokinet
studi
observ
clinic
relev
interact
oseltamivir
immunosuppress
drug
tacrolimu
cyclosporin
mycophenol
use
peramivir
iv
zanamivir
consid
case
lifethreaten
infect
concern
oral
absorpt
although
experi
drug
sot
recipi
lack
mention
use
inhibitor
treatment
influenza
longer
recommend
due
high
rate
resist
drug
rate
oseltamivir
resist
high
prepandem
influenza
viru
antivir
resist
occasion
describ
new
influenza
strain
immunosuppress
exposur
oseltamivir
risk
factor
develop
antivir
resist
resist
virus
patient
expos
oseltamivir
caus
mutat
result
increas
peramivir
retain
activ
zanamivir
resist
neuraminidas
inhibitor
uncommon
influenza
influenza
b
virus
commerci
avail
resist
assay
detect
mutat
may
occur
particularli
agent
oseltamivir
use
influenza
b
treat
resist
pattern
may
chang
affect
recommend
antivir
strategi
import
regularli
consult
nation
health
author
updat
recommend
virolog
epidemiolog
rsv
paramyxoviru
genu
pneumoviru
caus
season
annual
epidem
worldwid
year
round
diseas
seen
tropic
locat
two
year
age
virtual
children
experienc
primari
infect
although
reinfect
occur
throughout
life
risk
factor
sever
diseas
organ
transplant
includ
infect
children
year
age
underli
lung
diseas
earli
acquisit
rsv
transplant
augment
immunosuppress
associ
increas
sever
diseas
studi
transmiss
occur
inhal
infecti
droplet
contact
fomit
patient
known
suspect
rsv
isol
patient
use
standard
contact
precaut
prophylaxi
rsvspecif
monoclon
antibodi
palivizumab
high
titer
rsvigiv
shown
effect
specif
group
highrisk
infant
young
children
howev
studi
conduct
evalu
use
transplant
set
cost
weight
adjust
dose
product
adult
would
extrem
high
palivizumab
recommend
children
less
two
year
age
chronic
lung
diseas
cyanot
complic
congenit
heart
diseas
rsv
season
iii
howev
guidelin
regard
use
agent
older
children
adult
exist
survey
data
suggest
antibodybas
prophylaxi
commonli
use
among
pediatr
transplant
center
approv
vaccin
prevent
rsv
given
limit
data
treatment
rsv
support
care
recommend
reduct
immun
suppress
consid
particularli
sever
diseas
role
specif
antivir
treatment
controversi
ribavirin
shown
vitro
activ
rsv
aerosol
form
drug
approv
treatment
lower
respiratori
tract
diseas
due
rsv
certain
atrisk
popul
despit
fda
approv
convinc
data
describ
clinic
efficaci
agent
lack
consensu
treatment
rsv
diseas
current
exist
publish
data
treatment
rsv
diseas
sot
recipi
limit
data
pertain
lung
transplant
recipi
experi
stem
cell
transplant
popul
suggest
use
aerosol
ribavirin
may
reduc
mortal
associ
sever
rsv
infect
particularli
affect
lower
airway
combin
aerosol
ribavirin
antibodybas
intervent
includ
igiv
rsvig
palivizumab
appear
even
greater
impact
mortal
mani
expert
therefor
would
recommend
use
combin
ribavirin
antibodi
prepar
without
corticosteroid
treatment
sever
rsv
infect
base
upon
publish
experi
pediatr
organ
transplant
recipi
patient
without
risk
factor
sever
diseas
upper
respiratori
infect
unlik
benefit
aerosol
ribavirin
also
publish
report
success
treatment
rsv
lung
transplant
recipi
oral
iv
ribavirin
without
corticosteroid
studi
need
determin
clinic
efficaci
altern
sinc
risk
advers
effect
notabl
hemolyt
anemia
parainfluenza
pneumoviru
type
commonli
caus
diseas
human
type
piv
type
tend
circul
sporad
fall
winter
month
temper
area
type
occur
year
round
type
least
commonli
isol
epidemiolog
still
defin
transmiss
occur
via
persontoperson
spread
direct
contact
infecti
secret
fomit
diseas
seriou
particularli
pediatr
transplant
recipi
lung
transplant
recipi
age
although
respiratori
virus
associ
increas
risk
progress
oblit
bronchiol
lung
transplant
recipi
associ
appear
clearest
strongest
piv
lower
tract
diseas
patient
known
suspect
piv
isol
patient
use
standard
contact
precaut
approv
vaccin
recogn
prevent
antivir
agent
although
use
igiv
ribavirin
associ
benefit
manag
piv
infect
stem
cell
transplant
recipi
ribavirin
vitro
activ
use
treat
lung
transplant
recipi
lower
tract
diseas
expert
also
consid
use
igiv
corticosteroid
well
human
metapneumoviru
discov
rna
paramyxoviru
clinic
pattern
similar
rsv
signific
caus
diseas
transplant
recipi
pneumovirus
vaccin
prevent
focus
tight
infect
control
measur
includ
contact
precaut
case
report
anim
data
suggest
ribavirin
without
immunoglobulin
consid
manag
sever
case
hmpv
support
care
remain
mainstay
treatment
human
rhinovirus
member
picornavirida
famili
common
caus
cold
adult
children
recogn
caus
clinic
signific
diseas
transplant
recipi
fatal
case
describ
fatal
associ
coinfect
prolong
shed
minim
symptom
describ
particularli
lung
transplant
recipi
clinic
import
prolong
shed
fulli
defin
although
could
potenti
pose
threat
nosocomi
transmiss
current
approv
prevent
therapeut
intervent
use
molecular
diagnost
wider
rang
respiratori
virus
isol
mani
virus
newli
recogn
variant
coronaviru
polyomavirus
wu
ki
virus
bocaviru
wide
studi
transplant
recipi
clinic
impact
fulli
assess
sever
sometim
fatal
case
virus
immunocompromis
patient
recogn
consid
differenti
diagnosi
patient
present
sever
lower
tract
diseas
newer
agent
challeng
diagnos
sinc
includ
routin
clinic
avail
diagnost
test
addit
optim
manag
agent
defin
although
respiratori
virus
increasingli
recogn
caus
morbid
mortal
transplant
recipi
still
much
learn
impact
virus
prospect
studi
use
molecular
diagnost
need
understand
true
epidemiolog
clinic
spectrum
respiratori
viral
diseas
particular
studi
longterm
consequ
infect
even
mild
asymptomat
need
particularli
import
lung
transplant
recipi
lower
tract
infect
associ
increas
risk
chronic
reject
bronchiol
obliteran
syndrom
prospect
studi
use
contemporari
molecular
diagnost
tool
includ
metagenom
also
need
defin
efficaci
cost
prevent
intervent
particularli
high
risk
pediatr
popul
lung
transplant
recipi
novel
therapeut
agent
also
develop
may
use
sot
popul
prospect
trial
need
defin
optim
time
durat
treatment
regimen
virus
